2024年ESGO会议选择齐鲁制药的iparomlimab和tuvonralimab用于宫颈癌治疗的II期试验。 2024 ESGO Conference selects Qilu Pharmaceutical's Phase II trial of iparomlimab and tuvonralimab for cervical cancer treatment.

齐鲁制药的iparomlimab和tuvonralimab（QL1706）治疗宫颈癌的II期临床试验入选欧洲妇科肿瘤学会（ESGO）2024年会议上进行口头报告。 Qilu Pharmaceutical's Phase II clinical trial of iparomlimab and tuvonralimab (QL1706) for cervical cancer was selected for oral presentation at the European Society of Gynecological Oncology (ESGO) 2024 Conference. 这项由 Liu 和 Lou 教授领导的研究涉及 148 名患者，在治疗对免疫疗法无反应的复发性或转移性宫颈癌方面显示出有希望的结果。 The study, led by professors Liu and Lou, involved 148 patients and showed promising results in treating recurrent or metastatic cervical cancer unresponsive to immunotherapy.